Position in AMRX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$3,817,700
+$2,381,620 QoQ
Shares Held
307,136
+73.0% QoQ
Ownership
0.096%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
8 quarters on record
Voting authority
Sole 91.03849760366744.ToString("F0")%
Shared 0.ToString("F0")%
None 8.96150239633257.ToString("F0")%
Common Shares in AMRX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Trexquant Investment LP holds $120,085,995 across 26 Drug Manufacturers - Specialty & Generic names. AMRX ranks #11 (3.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
183,310 | $24,149,259 | |
| 2 | LQDA |
Liquidia Corp
|
409,259 | $15,445,434 | |
| 3 | VTRS |
Viatris Inc
|
882,688 | $11,925,114 | |
| 4 | PRGO |
PERRIGO Co plc
|
1,011,832 | $10,867,075 | |
| 5 | ZTS |
Zoetis Inc.
|
71,386 | $8,438,539 | |
| 6 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
135,280 | $6,513,732 | |
| 7 | XERS |
Xeris Biopharma Holdings, Inc.
|
833,217 | $4,832,658 | |
| 8 | EBS |
Emergent BioSolutions Inc.
|
524,233 | $4,351,133 |
All Filings in AMRX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,817,700 | 307,136 | Shares | Sole | 2026-05-15 | |
| 2025-06-30 | $1,436,080 | 177,513 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $5,282,341 | 630,351 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $3,664,742 | 462,720 | Shares | Sole | 2025-02-12 | |
| 2024-09-30 | $1,993,155 | 239,562 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $377,558 | 59,458 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $1,419,300 | 234,208 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $64,572 | 10,638 | Shares | Sole | 2024-02-09 | |
| No filing history on record for this holder in this stock. | ||||||